Press Releases


Prescription Justice Announces Its Support For the Affordable and Safe Prescription Drug Importation Act of 2024

 

Brooklyn, NY – June 28, 2024. Today, Representative Jan Schakowsky (D-IL) introduced the Affordable and Safe Prescription Drug Importation Act of 2024, which amends Section 804 of the Food, Drug and Cosmetic Act, to allow for new channels of safe importation beyond Canada to include the European Union, Switzerland, and the United Kingdom.


Prescription Justice Statement of Support for Florida’s Canadian Wholesale Drug Importation Program

 

Brooklyn, NY, January 10, 2024 -- Last week, the FDA approved Florida’s Canadian wholesale drug importation program. Brand name drug prices are substantially lower in Canada, providing Florida with an opportunity to save an estimated 150 million dollars annually. The law, Section 804 of the Food, Drug, and Cosmetic Act has permitted wholesale importation from Canada since 2003, but only subject to certification by the Secretary of Health and Human Services that the importation would pose no additional risk and it would achieve substantial savings.


Prescription Justice Statement of Support of Inflation Reduction Act

 

Brooklyn, NY, August 17, 2022 -- The Inflation Reduction Act was signed into law by President Joe Biden on Tuesday, August 16, 2022. It will substantially reduce drug prices and out-of-pocket spending in Medicare through price negotiation of those drugs with the highest expenditures; mandatory rebate rules to prevent drug companies from increasing drug prices above the consumer price index; and capping out-of-pocket drug costs for Medicare enrollees to $2000.


Prescription Justice Board of Directors Statement on H.R. 3

 

April 25, 2021 — Prescription Justice strongly supports the re-introduction of the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3). If enacted into law, it will end the crisis of high drug prices in America while adding new targeted public financing for pharmaceutical innovation.


Prescription Justice Introduces New 2020 Congressional Report Card On Drug Prices

 

August 4, 2020 — Prescription Justice, a non-partisan, nonprofit organization dedicated to lowering drug prices in America, today introduced its new 2020 Congressional report card on drug prices. Using a dynamic, multi-factor methodology, members of the House and Senate are scored and assigned a letter grade, A through F.


Prescription Justice Announces New Report Card or Senators on Prescription Drug Prices

 

October 17, 2019 — Prescription Justice, a non-partisan nonprofit organization dedicated to lowering drug prices in America, has published a Congressional report card on drug prices. This first of its kind Congressional report card on drug prices can help voters and political organizations determine who they want to support in upcoming elections.


Healthcare Providers Urge the Federal Government Not to Stop Medication Imports
 

April 10, 2018 — More than 50 health professionals, including physicians, physician assistants and nurse practitioners, signed a letter to President Donald Trump, members of Congress and the U.S. Food and Drug Administration (FDA) urging them to expressly permit personal prescription importation. The letter also demands that the FDA halt any actions that would impede access to safe and affordable medications from licensed pharmacies in other countries. Millions of Americans ...


Prescription Justice Coalition Sends Letter to Congress in Support of Safe Drug Importation

June 8, 2017 - Yesterday, in a letter to all members of Congress, non-profit organizations representing millions of Americans and their families stated their strong support for the Affordable and Safe Prescription Drug Importation Act of 2017. This critical legislation would expand access to lower-cost medications from Canada and other countries.


Prescription Justice Releases First Rx Rip-offs Report Detailing the Top 12 Highest Dollar Prescription Drug Price Hikes

April 12, 2017 - With the crisis over prescription drug prices intensifying in the United States, Prescription Justice today released a new analysis of the top 12 drugs with the highest dollar price increases over the past five years.


Americans Overwhelmingly Agree with President Trump That Prescription Drug Prices Are Too High, New Prescription Justice Poll Finds

February 21, 2017 - Americans agree with President Donald Trump that prescription drug prices in the United States are excessively high and support government action to bring down costs for consumers, per a new poll by Prescription Justice, a non-profit organization dedicated to lowering drug prices in America and advocating on behalf of the millions of Americans who already access affordable imported medications.


45 Million Americans Forego Medications Due to Costs, New Analysis Shows – 9 Times the Rate of the UK

February 6, 2017 - About 45 million Americans did not fill a prescription in 2016 due to the costs of pharmaceuticals, a new analysis by Prescription Justice shows, with 18% of adults reporting this problem in a recent survey.  This rate of foregoing medicine due to cost is nine times higher than in the United Kingdom, where medicine is largely covered by national health insurance. The analysis conducted by Prescription Justice —a non-profit organization dedicated to tackling...

 


Prescription Justice Action Group (PJAG) Publishes Consumer Guidance for Americans to Reclaim Personally Imported Medications Seized by FDA

November 19, 2015 - The Prescription Justice Action Group (PJAG) announced the publication of guidance on its website, www.pjag.org, to help American consumers challenge the U.S Food and Drug Administration (FDA) if their imported prescription drug orders are intercepted and threatened with destruction. Due to the high price of medicine in the U.S., about five million Americans import medication for personal use each year according to a survey by the U.S. Centers for Disease Control and Prevention. Many of the orders are placed using online pharmacies.

Stay informed about news and advocacy centered on the crisis of high drug prices